Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A100625-50mg | 50mg | In stock | $9.90 | |
A100625-250mg | 250mg | In stock | $18.90 | |
A100625-1g | 1g | In stock | $58.90 | |
A100625-5g | 5g | In stock | $229.90 | |
A100625-25g | 25g | In stock | $1,034.90 |
Potent DNMT1 inhibitor. Induces DNA hypomethylation.
Synonyms | 5-azacytidine|Azacitidine|320-67-2|Ladakamycin|Azacytidine|Vidaza|Mylosar|5-azacitidine|Azacitidina|Azacitidinum|Azacitidinum [INN-Latin]|5-AZAC|Azacitidina [INN-Spanish]|Antibiotic U 18496|C8H12N4O5|Onureg|NSC-102816|U-18496|CCRIS 60|4-Amino-1-beta-D-rib |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Action Type | INHIBITOR |
Mechanism of action | DNA (cytosine-5)-methyltransferase 1 inhibitor |
ALogP | -2.2 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488180979 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488180979 |
IUPAC Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
INCHI | InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 |
InChi Key | NMUSYJAQQFHJEW-KVTDHHQDSA-N |
Canonical SMILES | C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N |
Isomeric SMILES | C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N |
WGK Germany | 3 |
RTECS | XZ3017500 |
PubChem CID | 9444 |
Molecular Weight | 244.2 |
Beilstein | 620461 |
Reaxy-Rn | 620461 |
DrugBank Ligand | DB00928 |
---|---|
PubChem CID | 9444 |
CAS Registry No. | 320-67-2 |
ChEMBL Ligand | CHEMBL1489 |
Wikipedia | Azacitidine |
ChEBI | CHEBI:2038 |
RCSB PDB Ligand | 5AE |
DrugCentral Ligand | 25 |
PubChem SID | 488180979 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F2302726 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302721 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302720 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302719 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302718 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302717 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302716 | Certificate of Analysis | Jan 10, 2023 | A100625 |
F2302714 | Certificate of Analysis | Jan 10, 2023 | A100625 |
K1812067 | Certificate of Analysis | Sep 15, 2022 | A100625 |
F1828085 | Certificate of Analysis | Apr 27, 2022 | A100625 |
C2218077 | Certificate of Analysis | Jan 24, 2022 | A100625 |
C2218075 | Certificate of Analysis | Jan 24, 2022 | A100625 |
C2218073 | Certificate of Analysis | Jan 24, 2022 | A100625 |
C2218072 | Certificate of Analysis | Jan 24, 2022 | A100625 |
B2219237 | Certificate of Analysis | Jan 15, 2022 | A100625 |
B2219236 | Certificate of Analysis | Jan 15, 2022 | A100625 |
B2219233 | Certificate of Analysis | Jan 15, 2022 | A100625 |
Solubility | Soluble in water |
---|---|
Sensitivity | heat & light sensitive |
Melt Point(°C) | 228-230°C |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H302:Harmful if swallowed H340:May cause genetic defects H350:May cause cancer |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P201:Obtain special instructions before use. P308+P313:IF exposed or concerned: Get medical advice/attention. P281:Use personal protective equipment as required. P403:Store in a well-ventilated place. P270:Do not eat, drink or smoke when using this product. P202:Do not handle until all safety precautions have been read and understood. P330:Rinse mouth. P301+P312:IF SWALLOWED: call a POISON CENTER/doctor/... IF you feel unwell. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
WGK Germany | 3 |
RTECS | XZ3017500 |
Reaxy-Rn | 620461 |
Merck Index | 887 |
1. Stresemann C, Lyko F. (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.. Int J Cancer, 123 (1): (8-13). [PMID:18425818] |
2. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast Jr RC. (2011) Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.. Cancer, 117 (19): (4424-38). [PMID:21491416] |
3. Dear AE. (2016) Epigenetic Modulators and the New Immunotherapies.. N Engl J Med, 374 (7): (684-6). [PMID:26886527] |
4. Jones PA, Taylor SM. (1980) Cellular differentiation, cytidine analogs and DNA methylation.. Cell, 20 (1): (85-93). [PMID:6156004] |
5. Chen J et al.. (2019) 5-Aza-CdR Regulates RASSF1A By Inhibiting DNMT1 To Affect Colon Cancer Cell Proliferation, Migration And Apoptosis.. Cancer Manag Res, 11 (9517-9528). [PMID:31807076] |
6. Schwenzer H et al.. (2021) LARP1 isoform expression in human cancer cell lines.. RNA Biol, 18 (2): (237-247). [PMID:32286153] |
7. Fort RS et al.. (2018) Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.. BMC Cancer, 18 (127). [PMID:29394925] |
8. Nam H et al.. (2022) Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERBα.. Nat Commun, 13 (1972). [PMID:35418126] |
9. Alarcón MA et al.. (2020) The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer.. Int J Mol Sci, 21 (24): [PMID:33322837] |
10. Jacobs AH. (1977) The skin in childhood.. Hosp Pract, 12 (8): (91-112). [PMID:142744] |